Skip to main content

Table 2 PTEN pathway protein levels across groups and by ASD and PTEN status

From: Cross-level analysis of molecular and neurobehavioral function in a prospective series of patients with germline heterozygous PTEN mutations with and without autism

  (1) Macro-ASD (2) PTEN no-ASD (3) PTEN-ASD F (p) R2 ASD PTEN
M (SD) n = 20 M (SD) n = 16 M (SD) n = 25 β (p) β (p)
PTEN 140.5 (41.7) 121.1 (50.8) 116.4 (47.4) 1.59 (.213) .05  − .04 (.754)  − .24 (.045)
P- AKT 115.3 (42.0) 126.5 (36.2) 122.1 (38.5) 0.38 (.686) .01  − .05 (.722) .08 (.568)
Total AKT 133.4 (75.3) 139.1 (64.3) 126.3 (64.9) 0.18 (.838) .01  − .08 (.561)  − .05 (.730)
P- ERK 110.0 (57.0) 130.0 (67.8) 105.3 (54.2) 0.90 (.411) .03  − .19 (.196)  − .04 (.790)
Total ERK 195.4 (79.5) 194.5 (70.1) 183.9 (72.5) 0.17 (.847) .01  − .06 (.657)  − .08 (.606)
IGFBP2 166.1 (41.3) 180.4 (41.7) 156.5 (54.4) 1.25 (.295) .04 .22 (.120)  − .69 (.498)
MnSOD 175.5 (48.9) 202.2 (41.0) 160.5 (46.9) 4.00 (.024) .12  − .38 (.006)  − .15 (.284)
P- S6 94.6 (58.6) 67.1 (33.8) 115.5 (59.3) 3.54 (.035) .11 .36 (.010) .17 (.226)
S6 160.4 (47.6) 145.2 (52.0) 131.7 (43.4) 2.07 (.136) .07  − .13 (.373)  − .28 (.047)
EIF2A 17.8 (5.1) 19.9 (4.1) 19.9 (4.5) 1.54 (.222) .05  − .01 (.962) .22 (.120)
p27 13.7 (5.7) 16.4 (6.6) 12.8 (7.4) 1.43 (.248) .05  − .24 (.100)  − .07 (.649)
P-AKT/AKT 1.22 (1.11) 1.17 (0.84) 1.22 (0.64) 0.02 (.978)  < .01 .05 (.848)  < .01 (.999)
P-ERK/ERK 0.87 (0.95) 0.91 (0.90) 0.80 (0.69) 0.10 (.903)  < .01  − .12 (.666)  − .08 (.770)
P-S6/S6 0.64 (0.44) 0.52 (0.27) 0.88 (0.42) 4.40 (.017) .13 .36 (.007) .24 (.045)
  1. All protein levels are 10-e + 3. Bold designates p < .05, and italics designates p ≤ .10. Per a priori hypothesis, a one-tailed p value was used for evaluating the effect of PTEN mutations status on PTEN protein levels